Triple

T1351576
Position Surface form Disambiguated ID Type / Status
Subject Fampyra E28893 entity
Predicate hasActiveIngredient P12771 FINISHED
Object fampridine
Fampridine is a potassium channel blocker medication primarily used to improve walking in adults with multiple sclerosis.
 E153840 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: fampridine | Statement: [Fampyra, hasActiveIngredient, fampridine]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: fampridine
Context triple: [Fampyra, hasActiveIngredient, fampridine]
  • A. Tecfidera
    Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
  • B. Tysabri
    Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
  • C. riluzole
    Riluzole is a neuroprotective medication that modestly prolongs survival and slows disease progression in people with amyotrophic lateral sclerosis (ALS).
  • D. Spinraza
    Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
  • E. rivastigmine
    Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: fampridine
Triple: [Fampyra, hasActiveIngredient, fampridine]
Generated description
Fampridine is a potassium channel blocker medication primarily used to improve walking in adults with multiple sclerosis.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: fampridine
Target entity description: Fampridine is a potassium channel blocker medication primarily used to improve walking in adults with multiple sclerosis.
  • A. Tecfidera
    Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
  • B. Tysabri
    Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
  • C. riluzole
    Riluzole is a neuroprotective medication that modestly prolongs survival and slows disease progression in people with amyotrophic lateral sclerosis (ALS).
  • D. Spinraza
    Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
  • E. rivastigmine
    Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a498571d248190a0ac9eb02d97097f completed March 1, 2026, 7:49 p.m.
NER Named-entity recognition batch_69a4c26b1b4881908ae4b1b2c9b268a0 completed March 1, 2026, 10:49 p.m.
NED1 Entity disambiguation (via context triple) batch_69acc63eef908190aef058396f63a5a4 completed March 8, 2026, 12:43 a.m.
NEDg Description generation batch_69acc6dd15a481908cf870c87d469bc9 completed March 8, 2026, 12:46 a.m.
NED2 Entity disambiguation (via description) batch_69acc8072bb08190b1b7fb19fc2c0efc completed March 8, 2026, 12:51 a.m.
Created at: March 1, 2026, 7:56 p.m.